The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies — RECIPE

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Clinical Trial

Official title:
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial

Status Completed

Clinical Trial Summary

To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Polyradiculoneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trial Details

NCT number	NCT03864185
Study type	Interventional
Source	Nagoya University
Contact
Status	Completed
Phase	Phase 2
Start date	March 28, 2019
Completion date	May 27, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05363358` - A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Completed	`NCT03861481` - A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Phase 2
Active, not recruiting	`NCT05084053` - A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)	Phase 3
Completed	`NCT04051944` - A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Phase 2